2nd Next Generation Kinase Inhibitors Summit
Evvnt Promotion / evvnt
Archive
22.02.2023 - 23.02.2023 Boston Park Plaza, 50 Park Plaza, 02116 Boston, USA
Time: 8:00 am to 6:00 pm
Conference themes
With strong effectiveness profiles and 20 years of FDA approval, kinase inhibitors have revolutionized oncology treatment. The success of current kinase inhibitor classes is nevertheless constrained by rising resistance and security concerns.
With strong effectiveness profiles and 20 years of FDA approval, kinase inhibitors have revolutionized oncology treatment. The success of current kinase inhibitor classes is nevertheless constrained by rising resistance and security concerns.
Scientific Society
Hanson Wade
Hanson Wade
Notes
Speakers: Erik Schaefer, Co-Founder, President, Chief Executive Officer and Chief Scientific Officer, AssayQuant Technologies Inc., Gerhard Mueller, Chief Scientific Officer, Anavo Therapeutics, Harish Dave, Chief Medical Officer, AUM Biosciences
Speakers: Erik Schaefer, Co-Founder, President, Chief Executive Officer and Chief Scientific Officer, AssayQuant Technologies Inc., Gerhard Mueller, Chief Scientific Officer, Anavo Therapeutics, Harish Dave, Chief Medical Officer, AUM Biosciences
Enquiries and Registration:
https://go.evvnt.com/1446853-3?pid=4832
Mr. Min Ratcliffe
Health Services, Public Health
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International promotes access to education and training for all regardless of social, geographic and national borders."
